Of note, clinical trials of the MCT1 inhibitor AZD3965 in diffuse large B cell lymphoma and Burkitt's lymphoma, two typical MYC-driven cancer types, are currently ongoing [NCT01791595] (Figure 3). Here, SLC16A1 is linked to cancer.